First experience with Tolvaptan for the treatment of neonates and infants with capillary leak syndrome after cardiac surgery.

Anne KerlingOkan TokaAndré RüfferHanna MüllerSheeraz HabashChristel WeissSven DittrichJulia Moosmann

Published in: BMC pediatrics (2019)

In neonates and infants with diuretic-refractory CLS after cardiac surgery, additional aquaretic therapy with TLV showed an increase in urinary output and reduction in bodyweight in patients classified as TLV responder. Increase in urinary output and mean BP on day 2 of treatment were strong predictors for TLV response.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
stem cells
low birth weight
peritoneal dialysis
prognostic factors
bone marrow
replacement therapy
atrial fibrillation
preterm birth